Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Pereira, Lloyd ^a   Mariadason, John M ^b   Hannan, Ross D ^a,c   Dhillon, Amardeep S ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer stem cell; CRC; Epithelial mesenchymal transition; Serrated; Subtypes; Tumor progression

Indexed keywords

APC PROTEIN; B RAF KINASE; BETA CATENIN; BMI1 PROTEIN; CETUXIMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOID ENHANCER FACTOR 1; MICRORNA; MICRORNA 200; MICRORNA 34; MISMATCH REPAIR PROTEIN PMS2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN MLH1; PROTEIN MSH3; PROTEIN P53; SMAD4 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SIX1; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN; WNT1 PROTEIN; WNT3 PROTEIN;

CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HETEROGENEITY; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CPG ISLAND; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; METASTASIS; MISMATCH REPAIR; NUCLEAR REPROGRAMMING; ONCOGENE C MYC; PROTEIN EXPRESSION; RECTUM ADENOMA; REVIEW; TUMOR CELL PLASTICITY;

EID: 84923229776     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00013     Document Type: Review

References (89)

1. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol (2011) 6:479-507. doi: 10.1146/annurev-pathol-011110-130235
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell (1990) 61:759-67. doi:10.1016/0092-8674(90)90186-I
3. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (2014) 383:1490-502. doi:10.1016/S0140-6736(13)61649-9
4. Cadigan KM, Waterman ML. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol (2012) 4(11):a007906. doi:10.1101/cshperspect.a007906
5. Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, et al. Beta-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 151:1457-73. doi:10.1016/j.cell.2012.11.026
6. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell (2013) 152:25-38. doi:10.1016/j.cell.2012.12.012
7. Ong BA, Vega KJ, Houchen CW. Intestinal stem cells and the colorectal cancer microenvironment. World J Gastroenterol (2014) 20:1898-909. doi:10.3748/wjg.v20.i8.1898
8. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2009) 457:608-11. doi:10.1038/nature07602
9. Kanthan R, Senger JL, Kanthan SC. Molecular events in primary and metastatic colorectal carcinoma: a review. Pathol Res Int (2012) 2012:597497. doi:10.1155/2012/597497
10. Troiani T, Martinelli E, Napolitano S, Morgillo F, Belli G, Cioffi L, et al. Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. Curr Med Chem (2014) 21:1639-53. doi:10.2174/09298673113209990224
11. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics (2012) 5:66. doi:10.1186/1755-8794-5-66
12. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med (2009) 361:2449-60. doi:10.1056/NEJMra0804588
13. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol (2013) 231:63-76. doi:10.1002/path.4212
14. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer (2012) 12:260. doi:10.1186/1471-2407-12-260
15. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 19:614-8. doi:10.1038/nm.3174
16. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 19:619-25. doi:10.1038/nm.3175
17. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 10:e1001453. doi:10.1371/journal.pmed.1001453
18. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 487:330-7. doi:10.1038/nature11252
19. Vermeulen L, Snippert HJ. Stem cell dynamics in homeostasis and cancer of the intestine. Nat Rev Cancer (2014) 14:468-80. doi:10.1038/nrc3744
20. Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol (2014) 20:923-42. doi:10.3748/wjg.v20.i4.923
21. Brabletz T. To differentiate or not - routes towards metastasis. Nat Rev Cancer (2012) 12:425-36. doi:10.1038/nrc3265
22. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature (2013) 501:328-37. doi:10.1038/nature12624
23. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871-90. doi:10.1016/j.cell.2009.11.007
24. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 9:265-73. doi:10.1038/nrc2620
25. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science (2013) 342:1234850. doi:10.1126/science.1234850
26. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 17:1101-8. doi:10.1038/nm.2401
27. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 98:10356-61. doi:10.1073/pnas.171610498
28. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell (2012) 148:349-61. doi:10.1016/j.cell.2011.11.025
29. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell (2012) 22:725-36. doi:10.1016/j.ccr.2012.09.022
30. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell (2012) 22:709-24. doi:10.1016/j.ccr.2012.10.012
31. Aokage K, Ishii G, Ohtaki Y, Yamaguchi Y, Hishida T, Yoshida J, et al. Dynamic molecular changes associated with epithelial-mesenchymal transition and subsequent mesenchymal-epithelial transition in the early phase of metastatic tumor formation. Int J Cancer (2011) 128:1585-95. doi:10.1002/ijc.25500
32. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 133:704-15. doi:10.1016/j.cell.2008.03.027
33. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 3:e2888. doi:10.1371/journal.pone.0002888
34. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 8:511-24. doi:10.1016/j.stem.2011.02.020
35. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 22:571-84. doi:10.1016/j.ccr.2012.08.013
36. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer (2005) 5:744-9. doi:10.1038/nrc1694
37. Zheng H, Kang Y. Multilayer control of the EMT master regulators. Oncogene (2014) 33:1755-63. doi:10.1038/onc.2013.128
38. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol (2014) 16:488-94. doi:10.1038/ncb2976
39. Risolino M, Mandia N, Iavarone F, Dardaei L, Longobardi E, Fernandez S, et al. Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-beta-SMAD3 pathway in non-small cell lung adenocarcinoma. Proc Natl Acad Sci U S A (2014) 111:E3775-84. doi:10.1073/pnas.1407074111
40. Kouso H, Yano T, Maruyama R, Shikada Y, Okamoto T, Haro A, et al. Differences in the expression of epithelial-mesenchymal transition related molecules between primary tumors and pulmonary metastatic tumors in colorectal cancer. Surg Today (2013) 43:73-80. doi:10.1007/s00595-012-0344-0
41. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 4:9. doi:10.1186/1755-8794-4-9
42. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. Beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A (2011) 108:19204-9. doi:10.1073/pnas.1108977108
43. Kim YH, Kim G, Kwon CI, Kim JW, Park PW, Hahm KB. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-beta1. Oncol Rep (2014) 31:1380-8. doi:10.3892/or.2014.2970
44. Larriba MJ, Martin-Villar E, Garcia JM, Pereira F, Pena C, de Herreros AG, et al. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis (2009) 30:1459-68. doi:10.1093/carcin/bgp140
45. Pena C, Garcia JM, Larriba MJ, Barderas R, Gomez I, Herrera M, et al. SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue. Oncogene (2009) 28:4375-85. doi:10.1038/onc.2009.285
46. Pena C, Garcia JM, Silva J, Garcia V, Rodriguez R, Alonso I, et al. E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum Mol Genet (2005) 14:3361-70. doi:10.1093/hmg/ddi366
47. Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis (2013) 34:2548-57. doi:10.1093/carcin/bgt282
48. Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, et al. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One (2014) 9:e88950. doi:10.1371/journal.pone.0088950
49. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell (2007) 18:4615-24. doi:10.1091/mbc.E07-05-0406
50. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol (2010) 12:982-92. doi:10.1038/ncb2099
51. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle (2011) 10:4256-71. doi:10.4161/cc.10.24.18552
52. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 10:593-601. doi:10.1038/ncb1722
53. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia (2013) 15:180-91.
54. Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene (2014) 33:4077-88. doi:10.1038/onc.2013.370
55. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell (2009) 138:592-603. doi:10.1016/j.cell.2009.07.011
56. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 11:1487-95. doi:10.1038/ncb1998
57. Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest (2012) 122:3170-83. doi:10.1172/JCI63608
58. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 208:875-83. doi:10.1084/jem.20110235
59. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 13:317-23. doi:10.1038/ncb2173
60. Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle (2012) 11:1273-81. doi:10.4161/cc.19618
61. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 195:417-33. doi:10.1083/jcb.201103097
62. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal (2011) 4:ra71. doi:10.1126/scisignal.2001744
63. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol (2006) 8:1398-406. doi:10.1038/ncb1508
64. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1:651-61.
65. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mesenchymal transition in colorectal cancer: seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol (2012) 21:316-23. doi:10.1016/j.suronc.2012.08.003
66. Yusra , Semba S, Yokozaki H. Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells. Int J Oncol (2012) 41:201-10. doi:10.3892/ijo.2012.1459
67. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology (2006) 131:830-40. doi:10.1053/j.gastro.2006.06.016
68. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol (2007) 19:150-8. doi:10.1016/j.ceb.2007.02.007
69. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res (2012) 72:1547-56. doi:10.1158/0008-5472.CAN-11-3222
70. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 9:302-12. doi:10.1038/nrc2627
71. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int (2012) 2012:509348. doi:10.1155/2012/509348
72. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 268:1336-8. doi:10.1126/science.7761852
73. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology (2010) 138:1406-17. doi:10.1053/j.gastro.2009.12.010
74. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2014) 134:552-62. doi:10.1002/ijc.28387
75. Zhu J, Wang J, Shi Z, Franklin JL, Deane NG, Coffey RJ, et al. Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis. PLoS One (2013) 8:e79282. doi:10.1371/journal.pone.0079282
76. Sadanandam A, Wang X, de Sousa EMF, Gray JW, Vermeulen L, Hanahan D, et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle (2014) 13:353-7. doi:10.4161/cc.27769
77. Drabsch Y, ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev (2012) 31:553-68. doi:10.1007/s10555-012-9375-7
78. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 19:156-72. doi:10.1038/cr.2009.5
79. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology (2010) 138:2088-100. doi:10.1053/j.gastro.2009.12.066
80. Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L, et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell (2013) 24:15-29. doi:10.1016/j.ccr.2013.05.014
81. Patai AV, Molnar B, Tulassay Z, Sipos F. Serrated pathway: alternative route to colorectal cancer. World J Gastroenterol (2013) 19:607-15. doi:10.3748/wjg.v19.i5.607
82. Kahi CJ, Hewett DG, Norton DL, Eckert GJ, Rex DK. Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol (2011) 9:42-6. doi:10.1016/j.cgh.2010.09.013
83. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 107:1315-29. doi:10.1038/ajg.2012.161
84. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol (2011) 42:1-10. doi:10.1016/j.humpath.2010.06.002
85. Bond CE, Umapathy A, Buttenshaw RL, Wockner L, Leggett BA, Whitehall VL. Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers. PLoS One (2012) 7:e47483. doi:10.1371/journal.pone.0047483
86. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 36:744-52. doi:10.1097/PAS.0b013e31824430d7
87. Jass JR. Molecular heterogeneity of colorectal cancer: implications for cancer control. Surg Oncol (2007) 16(Suppl 1):S7-9. doi:10.1016/j.suronc.2007.10.039
88. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 65:6063-9. doi:10.1158/0008-5472.CAN-05-0404
89. Patil DT, Shadrach BL, Rybicki LA, Leach BH, Pai RK. Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. Mod Pathol (2012) 25:1423-31. doi:10.1038/modpathol.2012.98